Oestrogen receptors mediate the cellular response to oestrogens and related compounds and promote a wide range of effects on haemopoiesis. Polymorphisms of the oestrogen receptor genes have previously been associated with variation in bone mineral density, likelihood of fractures, risk of developing Alzheimer's disease, endometrial cancer and response to hormone replacement therapy. We examined the polymorphisms in both ERa and ERb genes in 108 patients receiving a bone marrow transplant from an HLA-matched sibling donor, and compared ER genotype with outcomes of occurrence of graft-versus-host disease (GVHD) and survival using logistic regression analysis. Polymorphism of ERa (presence of the PX haplotype (PvuII-XbaI RFLP) of intron 1), but not ERb, in the patient genotype associates with occurrence of acute GVHD and with lower overall survival, following correction for known clinical and genotypic risk features. Analysis of ER genotype prior to transplant might therefore inform on a patient's likelihood of developing post-transplant complications. Variation in transplant performance because of ER genotype suggests an underlying role for oestrogens in the pathophysiology of transplant-related complications, and suggests that oestrogen-related therapy may offer a new modality of post-transplant support.
The oestrogen receptors, ERa and the more recently identified ERb, are members of the steroid hormone receptor supergene family that includes the glucocorticoid receptor, vitamin A/retinol receptors, the thyroid hormone receptor and the vitamin D receptor (VDR). Both ERa and ERb bind their ligand (oestrogen) with high specificity and affinity, and thus activated, translocate to the nucleus to bind specific response elements on target genes. ERa and ERb can form both homodimers and functional heterodimers and recognise very similar, but not identical, DNA response elements. Both receptors show a wide tissue distribution which includes most cell and tissue types including haemopoietic cells, 1 with some tissues exhibiting a single receptor type, and others expressing both alpha and beta ER receptors. 2 The overall role of oestrogens in haematopoiesis is complex, given the range of tissue and cell types that express oestrogen receptors. Oestrogens appear to be required for the normal functioning of erythroid precursors 3 and are proposed to be downregulators of normal haematopoiesis, with reduced lymphopoiesis being seen during pregnancy 4 and an increase in lymphoid and myeloid cell production being seen in ovariectomised animals. 5 Exogenous oestrogen treatment also results in suppression of lymphopoiesis, and this negative regulation could be mediated by high-affinity oestrogen receptors. 6 In studies on male animals, ERa has been shown to promote the shift from precursor lymphocytes to mature cells for both B and T cells. 7 The oestrogen receptors are also involved in a wide range of biological responses, including repression of the inflammatory response. 8 Gene polymorphisms have been reported for both ERa and ERb genes, and associations have been reported between specific ER alleles and a number of biological characteristics, including variation in bone mineral density (BMD) [9] [10] [11] [12] [13] [14] [15] in normal subjects, risk of developing Alzheimer's disease (AD), 16, 17 and risk of developing endometrial cancer. 18 In the ERa gene (located at 6q24), variation in size of a (AT) microsatellite in the gene promoter region has been associated with variation in BMD, with alleles possessing a greater number of repeat elements being associated with increased BMD in both European 9 and Japanese 10 subjects. Restriction fragment length polymorphisms (RFLPs) for a PvuII and a XbaI restriction site in intron 1 have also been associated with alterations in BMD. Different populations of European origin 11, 12 show very similar allele frequencies at these loci, in contrast to oriental and Japanese populations, 13 which show markedly different allele fre-quencies. Consequently, although studies on both groups have shown gene associations with BMD, direct comparisons are difficult to make, and it has been suggested that some of these genetic associations may be population specific. In Japanese women, the ERa PvuII PP (À/À) genotype is associated with low BMD, 13 whereas in studies on a largely Caucasian population from the USA 12 or from Finland, 14 the PvuII pp (+/+) genotype was associated with low BMD. A single-nucleotide polymorphism (SNP) in codon 325 of the ERa gene has also been shown to associate with variation in calcium excretion in Japanese subjects. 15 The same RFLPs for PvuII and XbaI in intron 1 have also been associated with likelihood of developing AD, again with differences in the specific allelic associations being seen between Japanese 16 and European 17 subject groups. The XbaI RFLP genotype XX (À/À) has also been associated with a decreased risk of endometrial cancer in a Northern European study group, 18 and with variation in response to oestrogen replacement therapy for women with coronary disease. 19 In the ERb gene (located at 14q23), variations in the size of a (CA) microsatellite within intron 5 of the gene have been associated with variation in BMD 20 in a Japanese population. A number of uncommon polymorphisms have also been reported in the ERb genes of European individuals displaying extremes of body weight, with a nominal association of one common polymorphism (+1082) with anorexia nervosa. 21 The mechanism by which any of these polymorphisms affect ERb production has not yet been determined.
Since oestrogens affect haemopoiesis, and given that polymorphisms present in oestrogen receptor genes have been associated with oestrogen-related pathologies in a variety of studies, we hypothesised that polymorphism of oestrogen receptor genes ERa and ERb may be associated with variation in immune reconstitution and subsequent complications following bone marrow transplantation.
We compared ER genotypes of both patients and donors with the occurrence of GVHD and likelihood of death in patients receiving a BMT from an HLA-identical sibling donor.
We report that ERa genotype of the patient, but not the donor, associates with occurrence of acute GVHD and with likelihood of death in HLA-matched sibling-allo-BMT.
Materials and methods
ERa Gene. Polymorphisms at the intron 1 PvuII and XbaI sites, were investigated essentially as described by Becherini et al, 9 using a single PCR reaction whose product maps over both polymorphic restriction sites. In addition to determining allele identity at the PvuII and XbaI sites by restriction digestion of the PCR product, haplotypes were confirmed by double digestion with both enzymes. Polymorphism at the (AT) microsatellite in the gene promoter region was also investigated essentially as described by Becherini et al, 9 with PCR products being separated on 8% polyacrylamide gels with visualisation by silver staining.
ERb gene. Polymorphism at the (CA) microsatellite in intron 5 was investigated essentially as described by Ogawa et al, 20 with PCR products being separated on 8% polyacrylamide gels with visualisation by silver staining.
Polymorphisms at +1082 in exon 5 and +1730 in the 3 0 untranslated region of exon 8 were investigated by singlestrand conformational polymorphism (SSCP) analysis as described. 21 Allele nomenclature. All alleles were named as per the original reports described above. RFLPs for the ERa gene are categorised with an upper or lower case letter code, denoting the presence (p or x) or absence (P or X) of the restriction site for PvuII or XbaI, respectively. The X allele is the same as the IVS1 -401C allele reported in more recent studies, 19 with IVS1 -401T ¼ x allele. In the ERa gene, microsatellite alleles are identified with a number code corresponding to the number of repeat elements present in that allele (14, 23 etc) . For the ERb gene microsatellite, each allele is given a letter code (A-O) which distinguishes individual alleles in the series, for example, allele D ¼ 21 repeats, allele E ¼ 22 repeats, etc. as described in the original report of this polymorphism. 20 SNPs in the ERb gene were identified as G or A as in the original report. 21 Cytokine gene polymorphisms. All cytokine gene polymorphisms determined for this patient group were carried out as previously described, namely, TNFd and IL-10, 22 IL-6 and IFN-g, 23 IL-1Ra, 24 VDR. 25 
Patients, donors and normal controls
A panel of 100+ DNAs derived from normal individuals was used to establish allele frequencies for our local population (NE England).
Patients and donors:
We used an existing panel of transplant recipients and donors previously studied and reported by our group, to allow us to compare ER gene status with a number of other features implicated in the pathophysiology of graft-versus-host disease and clinical performance of allo-BMT. Stored DNA was available on 108 transplants patients and 79 of their donors, transplanted between 1983 and 2001. All patients were transplanted for haematopoietic malignancy, with acute leukaemia and chronic myeloid leukaemia (CML) being the most common underlying diagnoses (AML 46; ALL 22; CML 27; CMML 1; NHL 5; MDS 1; MM 3; HD 3). Patients transplanted either in CR1 of acute leukaemia (excluding Philadelphia-positive or secondary leukaemias) or in CP1 of CML were considered in early-stage disease, with the remaining patients (18) considered to be in advanced-stage disease (accelerating phase, blast crises, second CR, etc). Median recipient age was 29 years and that of donors was 28 years. In total, 67 patients were male, 33 of which received a female graft.
HLA-matching had been performed serologically for HLA-A and -B antigens and by high-resolution molecular typing for HLA-DRB1. Conditioning was as by protocol for disease and stage, briefly, 75 patients were conditioned with fractionated total body irradiation (TBI) (total 1200 cGy) and either cyclophosphamide (60 mg/kg Â 2) (pre-1990; n ¼ 46) or melphalan (3 mg/kg) (post-1989; n ¼ 29). TBI was avoided for patients who had received prior radiotherapy or had CML: 20 patients received busulphan (4 mg/kg Â 4) in combination with cyclophosphamide (n ¼ 9) or melphalan (n ¼ 11). A patient with AML in CR2 received melphalan and etoposide (1800 mg), and a patient with Hodgkin's disease received melphalan, etoposide and BCNU (300 mg/m 2 ). Two patients received melphalan and fludarabin, one patient received melphalan and etoposide and one patient received melphalan/VP16/ BCNU. One hypoplastic MDS patient received cyclophosphamide alone. Details of preconditioning were not available on six patients, but as preconditioning was not a variable considered in the study, these patients were included in the analysis.
All grafts were T-cell replete. GVHD prophylaxis consisted of 3 mg/kg cyclosporin A (CyA), either alone (n ¼ 80) or together with other drugs (n ¼ 28) for patients at higher risk of GVHD (determined by skin explant model 26 or by advanced recipient age and/or multiparous female donor with male recipient). Additional prophylaxis consisted of CsA supplemented with methotrexate 27 (MTX) in 18 patients; corticosteroids (CS) in four; antithymocyte globulin (ATG) in four; MTX and ATG in one; CS and ATG in one.
AGVHD was diagnosed using conventional criteria, 28 and was deemed analysable in those who survived for more than 30 days from BMT or who died prior to this with significant aGVHD, defined as that of grade II or above. In all, 25 patients developed no aGVHD, 32 patients grade I, 29 patients grade II, 21 patients developed grade III or IV of aGVHD which was considered severe. One patient died before day 30 with no GVHD. Chronic GVHD was diagnosed in patients who survived beyond +100 days using established criteria. 29 A number of clinical and genotypic features have been previously identified in this study group, which show associations with GVHD. Clinical variables include patient age (over 40), gender mismatch (female donor graft into male recipient), advanced-stage disease and use of additional prophylaxis. Genotypic variables for previously indicated and investigated risk factors associated with aGVHD in this patient study group include polymorphisms of: TNFd microsatellite, IL-10 promoter, IL-6 -174 promoter, IFN-g intron 1 microsatellite, IL-1Ra intron VNTR and VDR intron 8 25 (all cytokine gene polymorphisms previously associated with occurrence of GVHD are discussed in Dickinson et al 30 ).
Statistical analysis
Comparison of ER genotype with aGVHD grade was by Fisher's exact test (two-tailed). Tests of association of multiple variables with GVHD were carried out using binomial logistic regression and associations with survival by Cox regression. A stepwise backward procedure was used to identify potentially independent predictors of each end point. All possible predictors showing P40.5 were considered and were sequentially removed if, in the predictor model, P40.05. Plots of relative survival were carried out using Kaplan-Meier with log rank test (w 2 ). Pvalues less than 0.05 were regarded as statistically significant, and those between 0.05 and 0.1 as suggestive of a trend. All statistical analyses were performed using SPSS software (version 10).
Results

Allele frequency
As previously reported, the PvuII and XbaI polymorphisms were found to be in strong disequilibrium forming conserved haplotypes PX and px (linkage disequilibrium coefficient estimated in our population at 0.92). The polymorphic promoter region (AT) microsatellite was also found to have very similar allele distribution, in both control and transplant subjects, to other reported European populations, with the presence of distinct groups of low repeat number (13) (14) (15) (16) (17) (18) and high repeat number (19) (20) (21) (22) (23) alleles. The most common allele was allele 14. The high repeat copy number alleles (19) (20) (21) (22) (23) were found to be in partial linkage with the P and X alleles of the PvuII and XbaI RFLPs with the low repeat alleles being linked to the p and x alleles. When considering PvuII/XbaI haplotypes this relation was less pronounced, with high repeat element alleles being linked to both PX and non-PX (Px or pX) haplotypes.
ERb. Allele distribution for the intron 5 (CA) microsatellite showed similar patterns of distribution for our control and transplant groups. These allele frequencies were distinct for those of the original report, which was for a Japanese population. A large number of alleles were identified corresponding to alleles C to M in the original report. Allele frequencies for our normal population were: C 0.022, D 0.022, E 0, F 0.066, G 0.022, H 0.022, I 0.177, J 0.5, K 0.1, L 0.033, M 0.033. The most common allele reported in the Japanese population (allele E, 22 repeats) is very uncommon in our population collected from NE England. Allele frequencies for the +1082 and +1730 SNPs (+1082 G 0.954, A 0.046; +1730 G 0.65, A 0.35) were almost identical with those previously reported in a European population. 20 
ERa gene: association of ER genotype with aGVHD
The P and X alleles of the PvuII and XbaI RFLPs both showed associations with the occurrence of aGVHD when present in the patient's genotype. The strongest association was seen when comparing ERa haplotype (PX vs Px, pX and px) with occurrence of aGVHD. The PX haplotype occurred more frequently in those patients who developed moderate-to-severe GVHD (grade II-IV) than in those with no or mild aGVHD (see Table 1 ) (comparing ER genotype with aGVHD grade 0-I vs grade II-IV, P ¼ 0.034, Fisher's exact test (two-tailed)). This effect was seen both when comparing all patients in the study and when the analysis was restricted to those patients who did not receive additional prophylaxis.
Association of ERa genotype with aGVHD (grade II-IV) was examined after adjusting for other variables known to associate with occurrence of aGVHD by logistic regression analysis. Clinical variables included in the analysis were: patient age (over 40), gender mismatch (female donor graft into male recipient), advanced-stage disease, CMV status and use of additional prophylaxis. Genotypic variables included genotypes for: TNFd microsatellite, IL-10 promoter, IL-6 À174 promoter, IFN-g intron 1 microsatellite, IL-1Ra intron VNTR and VDR intron 8 25 (all cytokine gene polymorphisms previously associated with occurrence of GVHD are discussed in Dickinson et al 30 ). Subsequent multivariate analysis utilising logistic regression found that ERa genotype (PX +ve) was found to be significantly associated with grade II-IV aGVHD, as was patient age (440), IL-6 genotype (GG +ve), CMV status (patient or donor +ve) and gender mismatch (F to M). In the subgroup of patients who received CsA prophylaxis without additional agents (n ¼ 80), those factors that remained significantly associated with aGVHD were patient ER genotype (PX +ve) and IL-6 genotype (GG +ve) (see Table 2 ).
The ERa promoter region (AT) microsatellite showed no association with aGVHD in that both the allele and genotype frequencies observed showed similar distributions when comparing patient groups of differing occurrence of GVHD. No associations of GVHD were seen with either the PvuII/XbaI or (AT) microsatellite ERa genotypes of the transplant donors.
Chronic GVHD
No associations were seen between any of the polymorphisms tested (ERa or ERb gene) and the occurrence of chronic GVHD either with the patient or the donor genotype, that is, the various genotypes, for example, PX, px or microsatellite allele, etc, showed the same frequency distribution in patients who developed cGVHD and in those who did not.
Association of ERa genotype with survival
Survival analysis performed by comparing Kaplan-Meier plots of survival found that patients possessing a PX haplotype of the ERa gene showed a trend towards worse overall survival compared with those who did not possess this haplotype (P ¼ 0.069) (see Figure 1a) .
This analysis was repeated for the data set stratified into patients with evidence of relapse (n ¼ 16) and those with no relapse (n ¼ 92) in an effort to consider cause of death as a variable. Patients possessing a PX genotype appeared to be more likely to suffer early death from treatment-related causes, that is, causes other than relapse, than those lacking PX genotype (P ¼ 0.099) (see Figure 1b) . All patients in the small relapse group died within 100 months with no difference between those possessing or lacking a PX ER genotype.
Cox regression analysis was carried out to consider other variables previously shown to affect likelihood of survival and included patient age (440 years), gender mismatch (female donor into male patient), advanced-stage disease, ERa genotype (PX +ve), CMV status (donor or patient CMV positive) and donor VDR genotype (AA +ve). Characteristics significantly associating with overall survival were advanced-stage disease and donor VDR genotype, with both age and ER genotype continuing to show a trend towards association (see Table 3 ). Table 2 Binomial logistic regression analysis for features associating with aGVHD (grades II-IV) Comparison of ER genotype with aGVHD grade 0-I vs grade II-IV, P=0.034, Fisher's exact test (two-tailed).
ERb gene. Polymorphism of the ERb gene (the (CA) microsatellite in intron 5, SNPs at +1082 in exon 5 and +1730 in the 3 0 untranslated region of exon 8) did not show any association with GVHD, either acute or chronic, for either the patient or the donor genotype, in that the allele and genotype frequencies observed for both microsatellites and SNPs showed similar distributions when comparing patient groups differing in either occurrence or severity of GVHD. None of the ERb gene polymorphisms showed any associations with overall survival, either for the patient or donor genotypes (data not shown).
Discussion
We observed an association between patient genotype for the ERa gene and the occurrence of aGVHD, and a trend towards association between ERa genotype and reduced survival. These associations were apparent after correcting for other known variables by regression modelling.
In addition to the known clinical features that are associated with likelihood of a patient developing GVHD, a number of genetic features have recently been identified, including minor histocompatibility antigens and regulatory polymorphisms of cytokine genes. 30 It has been proposed that analysis of these features in a prospective transplant patient, in addition to more conventional features such as age, gender mismatch, etc, may form the basis of an individual patient risk assessment to guide subsequent support therapy. The strength of the associations reported in this current study of the ERa gene polymorphism would suggest that assessment of ERa gene status should be included in such risk index modelling.
Polymorphisms in the intron 1 region of the ERa gene are being linked to an increasing number of human pathologies, yet despite this interest the effect of the polymorphisms in intron 1 on ERa gene function is not known. Their position in an intron near the gene promoter might suggest a possible role in either transcription regulation (ERa gene transcription can occur from alternative promoters) 31 or mRNA processing and stability (numerous alternate splice variants of the primary ERa transcript are reported in human cells). 32 In studies on the effect of ERa genotype on response to hormone replacement therapy, patients who were homozygous for the IVS1 -401 C genotype (equating to the X genotype in the nomenclature used in our study) showed increased oestrogen responses compared to patients with other genotypes 19 (Xx and xx). If extrapolation of this genetic effect to the transplant setting were appropriate, it would suggest that the PX haplotypes in our study associating with aGVHD were because of increased signalling through the oestrogen receptor; antioestrogen therapy would therefore be indicated as a possible GVHD therapy in transplant patients.
No studies have yet been conducted on the role that oestrogen agonist/antagonists might have in bone marrow transplantation. However, there have been encouraging reports on the beneficial effect of tamoxifen on experimental models of autoimmune disease, which share a number of pathophysiological and mechanistic features with transplant-related complications such as GVHD. Tamoxifen treatment has shown beneficial effects on collagen-induced arthritis, 33 adjuvant-induced arthritis, 34 and on a model of systemic lupus erythematosus. 35, 36 As GVHD shares a number of mechanistic features with these disease states, it seems reasonable to suggest that tamoxifen therapy might potentially be used as a therapeutic modality for both assisting immune reconstitution and immunemediated transplant complications. The possible effect of ER genotype on survival also begs the question as to the mechanism of action of these effects. All deaths in the PX +ve group because of non-relapse causes occurred early in the study cohort, as would be expected for a patient rather than donor specific effect, and would be consistent with the hypothesis that the PX genotype predisposes an individual to sensitivity to treatment-related complications. Much larger studies would be needed in order to dissect this effect into its components of GVHD, infections, etc, given that most patients exhibit a clinically complex spectrum of symptoms and characteristics when suffering transplant-related complications.
Elucidation of the mechanism of action of these polymorphisms would clearly be of interest in studying the oestrogen receptor as a component in the promotion of immune reconstitution and aetiology of subsequent GVHD. It could be postulated that patients who possess the PX ERa haplotype may be more susceptible to lifethreatening complications such as haemorrhage due to low platelet count or infection due to reduced lymphopoiesis. Furthermore, the PX ERa haplotype may act indirectly, for example, by downregulating IL-6 production, an important cytokine involved in stem cell differentiation and lymphopoiesis. 37 It is recognised that T-cell depletion by positive selection of CD34+ stem cells is associated with reduced occurrence of GVHD after allogeneic transplantation, 38 but concomitantly T-cell depletion per se can also give rise to slower engraftment. 39 From the current knowledge of BMT immunobiology, it could therefore be suggested that novel therapy targeted at oestrogen function for improving immune reconstitution and reducing the incidence and severity of GVHD could be of value in post-transplant recovery protocols.
